Treatment of autoimmune hepatitis: Budesonide does not solve our problems
- 3 February 2023
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1071-1073
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Treatment and outcome of autoimmune hepatitis: Audit of 28 UK centresLiver International, 2022
- Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for PharmacogeneticsGenes, 2020
- Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis GroupJournal of Hepatology, 2020
- Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesHepatology, 2019
- Adverse events related to low dose corticosteroids in autoimmune hepatitisAlimentary Pharmacology & Therapeutics, 2019
- Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune HepatitisClinical Gastroenterology and Hepatology, 2018
- EASL Clinical Practice Guidelines: Autoimmune hepatitisJournal of Hepatology, 2015
- Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatmentJournal of Hepatology, 2011
- Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune HepatitisGastroenterology, 2010
- Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCCWorld Journal of Gastroenterology, 2003